BIBP 3226 trifluoroacetateCat. No. 2707 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: N-[(1R)]-4-[(Aminoiminomethyl)amino-1-[[[(4-hydroxyphenyl)methyl]amino]carbonyl]butyl-α-phenylbenzeneacetamide trifluoroacetate |
Biological Activity
Mixed non-peptide neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist (Ki values are 1.1, 79, 108, > 1000, > 1000 and >1000 for rNPY Y1, hNPFF2, rNPFF, rNPY Y2, rNPY Y4 and rNPY Y5 respectively). Produces an anxiogenic-like effect in rats following i.c.v. administration.Certificate of Analysis / Safety Data Sheet
References
Kask et al (1996) Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Eur.J.Pharmacol. 317 R3. PMID: 8997632.
Mollereau et al (2001) Agonist and antagonist activities on human NPFF2 receptors of the NPY ligands GR231118 and BIBP3226. Br.J.Pharmacol. 133 1. PMID: 11325787.
Fang et al (2006) In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides 27 2207. PMID: 16762456.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: BIBP 3226 trifluoroacetate, supplier, Mixed, NPFF, NPY, Y1, receptor, antagonists, Receptors, Neuropeptide, FF/AF, Y, BIBP3226, trifluoroacetate, npffr1, npffr2, npff1, npff2, neuropeptides
Quick Order
Find multiple products by catalog number
New Products in this Area
Oxytocin analog
ML 221Apelin receptor (APJ) antagonist
Q94 hydrochlorideNegative allosteric modulator at PAR1 receptor
FSLLRY-NH2PAR2 peptide antagonist
SB 611812Urotensin-II (UT) antagonist; attenuates cardiac dysfunction
TC-MCH 7cSelective melanin-concentrating hormone receptor 1 (MCH1R) antagonist
CYM 9484Potent NPY Y2 receptor antagonist
Twitter Updates
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.







